Canadian Biomaterials Society
La Société Canadienne des Biomatériaux

Dear CBS Members, The World Biomaterials Congress 2024 WBC2024 is soliciting recommendations for plenary speakers...

Through the BioInnovation Institute Science Prize for Innovation, the editors of Science seek to recognize bold researchers who are asking fundamental questions at the intersection of the life sciences and entrepreneurship...

We are pleased to open the call for applications for the CBS Mentorship and Professional Development, a program specifically designed to connect professionals outside of academia with graduate students and postdoctoral fellows coming from the Canadian biomaterial s community...

14th Intl Symposium on Biodegradable Metals for Applications on behalf of Professor Mantovani and the Quebec City Student Chapter Want to discover the next generation of bioresorbable metals aiming to bridge the gap between biomaterials and tissue engineering for pediatric, dental, orthopedic, vascular, cardiac, neurological applications, and more? The final program of the upcoming 14th Intl Symposium on Biodegradable Metals for Biomedical Applications is now online...

The innate immune response is the primary defense of the body against infection and injury, and is facilitated largely by white blood cells, such as macrophages...

Poly ethylene glycol PEG hydrogels have been widely studied as biomaterials, exploiting the hydrophilic, non-immunogenic, and non-cytotoxic properties of PEG...

Differences in the design features of the total knee replacements TKRs contribute to the implant performance1-3...

Knee osteoarthritis KOA is the most common osteoarthritis that affects over 10 of Canadians. It occurs in almost all demographics and individuals with injured articular cartilage AC are especially at risk of KOA development...

There is a significant need to evaluate the efficacy and safety of the potential drug candidates in early-stage of the development pipeline to prevent skyrocketing costs of failure in the late-stages of clinical trials or drugs attrition from the market 1...